

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 27/00	A2	(11) International Publication Number: WO 98/51354 -- (43) International Publication Date: 19 November 1998 (19.11.98)
<p>(21) International Application Number: PCT/US98/09951</p> <p>(22) International Filing Date: 15 May 1998 (15.05.98)</p> <p>(30) Priority Data: 60/046,589 15 May 1997 (15.05.97) US 09/039,107 14 March 1998 (14.03.98) US</p> <p>(71) Applicant: CREATIVE BIOMOLECULES, INC. [US/US]; 45 South Street, Hopkinton, MA 01748 (US).</p> <p>(72) Inventors: RUEGER, David, C.; 81 Pine Hill Road, Southborough, MA 01772 (US). TUCKER, Marjorie, M.; 132 Robert Road, Holliston, MA 01746 (US).</p> <p>(74) Agent: MEYERS, Thomas, C.; Testa, Hurwitz & Thibault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).</p>		<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: COMPOSITIONS FOR MORPHOGEN-INDUCED OSTEOGENESIS</p> <p>(57) Abstract</p> <p>Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOSITIONS FOR MORPHOGEN-INDUCED OSTEOGENESIS

Field of the Invention

The invention relates to materials and methods for correcting orthopedic defects using osteogenic proteins.

Background of the Invention

5 Morphogens are able to induce the proliferation and differentiation of progenitor cells into functional bone, cartilage, tendon, and/or ligament tissue. This class of proteins includes members of the family of bone morphogenetic proteins (BMPs) identified by their ability to induce ectopic, endochondral bone morphogenesis. The morphogens, also referred to as, osteogenic proteins generally are classified as a subgroup of the TGF- β superfamily of growth factors (Hogan (1996)
10 Genes & Development 10:1580-1594). Members of the morphogen family of proteins include the mammalian osteogenic protein-1 (OP-1, also known as BMP-7, and the *Drosophila* homolog 60A), osteogenic protein-2 (OP-2, also known as BMP-8), osteogenic protein-3 (OP-3), BMP-2 (also known as BMP-2A or CBMP-2A, and the *Drosophila* homolog DPP), BMP-3, BMP-4 (also known as BMP-2B or CBMP-2B), BMP-5, BMP-6 and its murine homolog Vgr-1, BMP-9,
15 BMP-10, BMP-11, BMP-12, GDF3 (also known as Vgr2), GDF8, GDF9, GDF10, GDF11, GDF12, BMP-13, BMP-14, BMP-15, GDF-5 (also known as CDMP-1 or MP52), GDF-6 (also known as CDMP-2), GDF-7 (also known as CDMP-3), the *Xenopus* homolog Vgl and NODAL, UNIVIN, SCREW, ADMP, and NEURAL.

Members of this family encode secreted polypeptides that share common structural
20 features. The mature form of such proteins results from processing through a "pro-form" to yield a mature polypeptide chain competent to dimerize and containing a carboxy terminal active domain of approximately 97-106 amino acids. All members share a conserved pattern of cysteines in this domain and the active form of these proteins can be either a disulfide-bonded homodimer of a single family member or a heterodimer of two different members (see, e.g.,
25 Massague (1990) Annu. Rev. Cell Biol. 6:597; Sampath, et al. (1990) J. Biol. Chem. 265:13198). See also, U.S. 5,011,691; U.S. 5,266,683, Ozkaynak et al. (1990) EMBO J. 9: 2085-2093,

- 2 -

Wharton et al. (1991) PNAS 88:9214-9218), (Ozkaynak (1992) J. Biol. Chem. 267:25220-25227 and U.S. 5,266,683); (Celeste et al. (1991) PNAS 87:9843-9847); (Lyons et al. (1989) PNAS 86:4554-4558). These disclosures describe the amino acid and DNA sequences, as well as the chemical and physical characteristics, of osteogenic proteins. See also, Wozney et al. (1988) Science 242:1528-1534); BMP 9 (WO93/00432, published January 7, 1993); DPP (Padgett et al. (1987) Nature 325:81-84; and Vg-1 (Weeks (1987) Cell 51:861-867).

True osteogenic proteins capable of inducing the above-described cascade of morphogenic events resulting in endochondral bone formation, have now been identified, isolated, and cloned. Whether naturally-occurring or synthetically prepared, these osteogenic factors, when implanted in a mammal in association with a matrix or substrate that allows attachment, proliferation and differentiation of migratory progenitor cells, can induce recruitment of accessible progenitor cells and stimulate their proliferation, thereby inducing differentiation into chondrocytes and osteoblasts, and further inducing differentiation of intermediate cartilage, vascularization, bone formation, remodeling, and, finally, marrow differentiation. Furthermore, numerous practitioners have demonstrated the ability of these osteogenic proteins, when admixed with either naturally-sourced matrix materials such as collagen or synthetically-prepared polymeric matrix materials, to induce bone formation, including endochondral bone formation, under conditions where true replacement bone otherwise would not occur. For example, when combined with a matrix material, these osteogenic proteins induce formation of new bone in large segmental bone defects, spinal fusions, and fractures.

Needs remain for carriers for delivering osteogenic protein to a bone repair locus. Preferred carriers are provided by the present invention.

Summary of the Invention

The present invention provides delivery systems and methods for providing osteogenic protein to bone defect sites. In a preferred embodiment, a delivery system of the invention comprises osteogenic protein in a calcium phosphate matrix. It has now been recognized that use of a calcium phosphate matrix for delivery of osteogenic protein to defect sites in bones that do not undergo active remodeling, especially in short, irregular, or flat bone defect sites, greatly improves the structure of new bone ingrowth. It has also been recognized that providing preferred ratios of calcium phosphate to hydroxyapatite results in improved cosmetic results.

The invention provides, in one aspect, a device for inducing local bone and/or cartilage formation. A preferred device of the invention comprises an osteogenic protein in a calcium phosphate matrix. As contemplated herein, the device preferably comprises osteogenic proteins such as, but not limited to, OP-1, OP-2, BMP-2, BMP-4, BMP-5 and BMP-6. A currently
5 preferred osteogenic protein is OP-1. As used herein, the terms "morphogen", "bone morphogen", "bone morphogenic protein", "BMP", "osteogenic protein" and "osteogenic factor" embrace the class of proteins typified by human osteogenic protein 1 (hOP-1). Nucleotide and amino acid sequences for hOP-1 are provided in Seq. ID Nos. 1 and 2, respectively. OP-1 is merely representative of the TGF- β subclass of true chondrogenic tissue morphogens competent
10 to act as osteogenic proteins, and is not intended to be limiting. Other known, and useful proteins include, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, NODAL, UNIVIN, SCREW, ADMP, NEURAL and osteogenically active amino acid variants thereof. In one preferred embodiment, proteins useful in
15 the invention include biologically active species variants of any of these proteins, including conservative amino acid sequence variants, proteins encoded by degenerate nucleotide sequence variants, and osteogenically active proteins sharing the conserved seven cysteine skeleton as defined herein and encoded by a DNA sequence competent to hybridize to a DNA sequence encoding an osteogenic protein disclosed herein, including, without limitation, OP-1, BMP-5,
20 BMP-6, BMP-2, BMP-4 or GDF-5, GDF-6 or GDF-7. In another embodiment, useful osteogenic proteins include those sharing the conserved seven cysteine domain and sharing at least 70% amino acid sequence homology (similarity) within the C-terminal active domain, as defined herein. In another embodiment, useful proteins include those sharing greater than 60% identity in the C-terminal domain. In still another embodiment, useful osteogenic proteins can be
25 defined as osteogenically active proteins having any one of the generic sequences defined herein, including OPX (SEQ ID No: 3) and Generic Sequences 7 and 8 (Seq. ID Nos. 4 and 5), or Generic Sequences 9 and 10 (Seq. ID Nos. 6 and 7).

A calcium phosphate matrix for use in the invention may be supplied in any biocompatible form, and is preferably in the form of hydroxyapatite, tricalcium phosphate, or any other form that
30 is resorbable during new bone growth. Calcium phosphate may be supplied in the form of a powder, solid blocks, cements, pastes, shaped forms, or any other form that is resorbed, in whole or in part, during new bone ingrowth. Calcium phosphate for use in a device or method of the

invention may be integrated or admixed with other carrier materials, such as collagen or a collagen-based carrier, including polyglycolic acid, polylactic acid, polybutyric acid, polysilicates, and their derivatives, or combinations.

In another aspect, the instant invention provides methods for inducing local bone or cartilage formation, or for repair of bone, cartilage or osteochondral defects. In a preferred embodiment, a method of the invention comprises administering to a bone defect site an osteogenic protein in a calcium phosphate matrix. It has now been discovered that a calcium phosphate matrix is superior to other matrices for repair of defects, especially in short, irregular, or flat bones. Accordingly, in a particularly preferred embodiment, the invention provides a method for inducing new bone growth in a small bone of the head, face, hands, or feet, comprising implanting an osteogenic device in a short, irregular, or flat bone defect site, the osteogenic device comprising an osteogenic protein in a calcium phosphate matrix in an amount sufficient to stimulate new bone growth in the defect site. Methods of the invention are particularly useful for providing augmentation of the bones of the face, such as, for example, the mandible or the maxilla. While a calcium phosphate matrix is useful for reconstruction of any bone, including long bones, methods of the invention are particularly useful in cosmetic surgery procedures, wherein precise bone reconstruction is desirable or required.

Also in a preferred embodiment, the invention provides methods for repairing a bone defect comprising filling the defect with a composition comprising a morphogen in combination with an allograft material, preferably allograft bone chips. In highly preferred embodiments, the invention comprises inserting an impacted allograft into a defect site in order to improve mechanical fixation of the implant.

The instant methods are useful to induce formation of at least endochondral bone, intramembranous bone, and articular cartilage. Bone repair methods of the invention include treatment of both closed and open defects with the above-described improved osteogenic devices. As taught herein, the methods of the instant invention can be practiced using improved devices that are of sufficient volume to fill the defect site, as well as using improved devices that are not. Examples of defects include, but are not limited to, critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, chondral defects and periodontal defects. Further aspects and advantage of the invention will be appreciated upon consideration of the following detailed description thereof.

Brief Description of the Drawings

Figure 1 (panels 1A through 1L) is a tabular alignment of the amino acid sequences of various naturally occurring morphogens with a preferred reference sequence of human OP1, residues 330-431 of SEQ ID NO: 1;

5 Figure 2 is a tabular presentation of alternative amino acids for "Xaa" positions in generic sequences SEQ ID NOS: 4, 5, and 8 that represent amino acid variations in known morphogens;

Figure 3 is a tabular presentation of alternative amino acids for "Xaa" positions in generic sequences SEQ ID NOS: 6, 7, and 9 that represent amino acid variations in known morphogens;

10 Figure 4 is a tabular presentation of alternative amino acids for "Xaa" positions in generic sequence SEQ ID NO: 3 that represents amino acid variations in several identified allelic and phylogenetic variants of OP-1 and OP-2.

Detailed Description of Preferred Embodiments

Bones are generally divided into four main types. Long bones are the largest bones of the body (e.g., the femur); short bones are shorter than long bones, and have less prominent ends
15 (e.g., bones of the hands and feet); irregular bones typically possess surfaces that articulate with other bones (e.g., wrist bones); and flat bones typically have plate-like surfaces (e.g., bones of the skull). It has now been discovered that bone repair is greatly facilitated by application to a defect site of an osteogenic protein in a calcium phosphate matrix. It has also been discovered that the use of an optimal ratio of calcium phosphate to osteogenic protein promotes optimal cosmetic
20 bone ingrowth. These effects are most prominent in short, irregular and flat bones, especially where optimal cosmetic results are desirable.

As used herein, "defect", "defect site", or "defect locus", defines an orthopedic structural disruption requiring repair. The defect may occur in a joint, in any bone, including a intramembranous bone, bony, cartilage, tendon, ligament, or an osteochondral defect. A defect
25 can be the result of accident, disease, surgical manipulation, and/or prosthetic failure. In certain embodiments, the defect is a void having a volume incapable of endogenous or spontaneous repair. Such defects are generally twice the diameter of the subject bone and are also called "critical size" defects. For example, in rabbit and monkey segmental defect models, the gap is approximately 1.5 cm and 2.0 cm, respectively. In a canine ulnar defect model, the defect is a 2-4

cm, gap incapable of spontaneous repair. See, e.g., Schmitz *et al.*, Clinical Orthopaedics and Related Research 205:299-308 (1986); Vukicevic *et al.*, in Advanced In Molecular and Cell Biology, Vol. 6, pp. 207-224 (1993)(JAI Press, Inc.). In other embodiments, the defect is a non-critical size segmental defect. Generally, non-critical defects, such as fracture defects, are capable of some spontaneous repair. Application of the devices and formulations described herein can substantially enhance fracture repair, including the rate and quality of newly formed bone. This allows for improved bone healing, especially in compromised individuals such as diabetics, smokers, obese individuals and others who, due to an acquired or congenital condition have a reduced capacity to heal bone fractures. Other defects include osteochondral defect, such as osteochondral plugs. Such a defect traverses the entirety of the overlying cartilage and enters, at least in part, the underlying bony structure. In contrast, a chondral or subchondral defect traverses the overlying cartilage, in part or in whole, respectively, but does not involve the underlying bone. Other orthopedic defects susceptible to repair using the instant invention include, but are not limited to, non-union fractures; bone cavities; tumor resection; fresh fractures (distracted or undistracted); cranial/facial abnormalities; periodontal defects and irregularities; spinal fusions; as well as those defects resulting from diseases such as cancer, arthritis, including osteoarthritis, and other bone degenerative disorders such as osteochondritis dessicans. Still other defects susceptible to repair include joint tissue defects, including defects requiring partial or complete joint reconstruction, including correcting tendon and/or ligamentous tissue defects such as, for example, the anterior, posterior, lateral and medial ligaments of the knee, the patella and achilles tendons, and the like.

In addition to osteogenic proteins, various growth factors, hormones, enzymes, therapeutic compositions, antibiotics, or other bioactive agents also can be contained within an osteogenic device. Thus, various known growth factors such as EGF, PDGF, IGF, FGF, TGF- α , and TGF- β can be combined with an osteogenic device and be delivered to the defect locus. An osteogenic device also can be used to deliver chemotherapeutic agents, insulin, enzymes, enzyme inhibitors and/or chemoattractant/chemotactic factors.

The means for making and using the methods, implants and devices of the invention, as well as other material aspects concerning their nature and utility, including how to make and how to use the subject matter claimed, will be further understood from the following, which constitutes the best mode currently contemplated for practicing the invention. It will be appreciated that the

invention is not limited to such exemplary work or to the specific details set forth in these examples.

I. PROTEIN CONSIDERATIONS

A. *Biochemical, Structural and Functional Properties of Bone Morphogenic Proteins*

5 In its mature, native form, natural-sourced osteogenic protein is a glycosylated dimer, typically having an apparent molecular weight of about 30-36 kDa as determined by SDS-PAGE. When reduced, the 30 kDa protein gives rise to two glycosylated peptide subunits having apparent molecular weights of about 16 kDa and 18 kDa. In the reduced state, the protein has no detectable osteogenic activity. The unglycosylated protein, which also has osteogenic activity,
10 has an apparent molecular weight of about 27 kDa. When reduced, the 27 kDa protein gives rise to two unglycosylated polypeptide chains, having molecular weights of about 14 kDa to 16 kDa. Typically, the naturally occurring osteogenic proteins are translated as a precursor, having an N-terminal signal peptide sequence typically less than about 30 residues, followed by a "pro" domain that is cleaved to yield the mature C-terminal domain. The signal peptide is cleaved
15 rapidly upon translation, at a cleavage site that can be predicted in a given sequence using the method of Von Heijne, NUCLEIC ACIDS RESEARCH 14: 4683-4691 (1986). The pro domain typically is about three times larger than the fully processed mature C-terminal domain.

Osteogenic proteins useful herein include any known naturally-occurring native proteins including allelic, phylogenetic counterpart and other variants thereof, whether naturally-occurring
20 or biosynthetically produced (*e.g.*, including "muteins" or "mutant proteins"), as well as new, osteogenically active members of the general morphogenic family of proteins.

Particularly useful sequences include those comprising the C-terminal 96 or 102 amino acid sequences of DPP (from *Drosophila*), Vgl (from *Xenopus*), Vgr-1 (from mouse), the OP-1 and OP-2 proteins (*see* U.S. Patent No. 5,011,691 and Oppermann *et al.*, as well as the proteins
25 referred to as BMP2, BMP3, BMP4 (*see* WO88/00205, U.S. Patent No. 5,013,649 and WO91/18098), BMP5 and BMP6 (*see* WO90/11366, PCT/US90/01630), BMP8 and BMP9. Other proteins useful in the practice of the invention include active forms of OP1, OP2, OP3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, GDF-5, GDF-6, GDF-7, DPP, Vgl, Vgr, 60A protein, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, BMP10, BMP11, BMP13, BMP15, UNIVIN,
30 NODAL, SCREW, ADMP or NURAL and amino acid sequence variants thereof. In one currently preferred embodiment, osteogenic protein include any one of: OP1, OP2, OP3, BMP2,

BMP4, BMP5, BMP6, BMP9, and amino acid sequence variants and homologs thereof, including species homologs, thereof. Publications disclosing OP-1 and OP-2 sequences, as well as their chemical and physical properties, include U.S. Patent Nos. 5,011,691 and 5,266,683, incorporated by reference herein.

5 In preferred embodiments, morphogens for use in methods of the invention include proteins having at least 70% homology with the amino acid sequence of the C-terminal seven-cysteine skeleton of human OP-1, SEQ ID NO: 2, and having the ability to induce endochondral bone formation in the Reddi and Sampath assay described herein. Compounds that meet these requirements are considered functionally equivalent to a known response morphogen. To
10 determine whether a candidate amino acid sequence is functionally equivalent to a reference morphogen, the candidate sequence and the reference sequence are aligned. The first step for performing an alignment is to use an alignment tool, such as the dynamic programming algorithm described in Needleman *et al.*, J. MOL. BIOL. 48: 443 (1970), and the Align Program, a commercial software package produced by DNASTar, Inc. the teachings of which are incorporated
15 by reference herein. After the initial alignment is made, it is then refined by comparison to a multiple sequence alignment of a family of related proteins, such as those shown in FIG. 1A through 1M, which is a multiple sequence alignment of a family of known morphogens, including hOP-1. Once the alignment between the candidate and reference sequences is made and refined, a percent homology score is calculated. The individual amino acids of each sequence are compared
20 sequentially according to their similarity to each other. Similarity factors include similar size, shape and electrical charge. One particularly preferred method of determining amino acid similarities is the PAM250 matrix described in Dayhoff *et al.*, 5 ATLAS OF PROTEIN SEQUENCE AND STRUCTURE 345-352 (1978 & Supp.), incorporated by reference herein. A similarity score is first calculated as the sum of the aligned pairwise amino acid similarity scores. Insertions and
25 deletions are ignored for the purposes of percent homology and identity. Accordingly, gap penalties are not used in this calculation. The raw score is then normalized by dividing it by the geometric mean of the scores of the candidate compound and the seven cysteine skeleton of hOP-1. The geometric mean is the square root of the product of these scores. The normalized raw score is the percent homology.

30 In an alternative preferred embodiment, a functionally-equivalent morphogen sequence shares at least 60% amino acid identity with a reference sequence. That is, any 60% of the aligned amino acids are identical to the corresponding amino acids in the reference sequence. Any

one or more of the naturally-occurring or biosynthetic morphogens disclosed herein may be used as a reference sequence to determine whether a candidate sequence falls within the morphogen family. In a preferred embodiment, the reference sequence is the C-terminal seven-cysteine skeleton sequence of human OP-1 as shown in SEQ ID NO: 2. Examples of conservative substitutions for use in the above calculations include the substitution of one amino acid for another with similar characteristics, *e.g.*, substitutions within the following groups are well-known: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine. The term "conservative variant" or "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid in a given polypeptide chain, provided that antibodies having binding specificity for the resulting substituted polypeptide chain also have binding specificity (*i.e.*, "crossreact" or "immunoreact" with) the unsubstituted or parent polypeptide.

In a preferred embodiment, morphogens useful in the present invention are defined by a generic amino acid sequence that represents variations in known morphogens. For example, SEQ ID NOS: 4 and 5 encompass observed variations between preferred morphogens, including OP-1, OP-2, OP-3, CBMP-2A, CBMP-2B, BMP-3, 60A, DPP, Vgl, BMP-5, BMP-6, Vgr-1, and GDF-1. SEQ ID NO: 5 includes all of SEQ ID NO: 4, and also includes at its N-terminus the five amino acid sequence of SEQ ID NO: 8. The generic sequences include both the amino acid identity shared by these sequences in the C-terminal domain, defined by the six- and seven-cysteine skeletons (SEQ ID NOS: 4 and 5, respectively), and alternative amino acids for variable positions within the sequence. Positions that allow for alternative amino acids are represented by "Xaa". FIG. 3 shows the alternative amino acids for each "Xaa" position in SEQ ID NOS: 4, 5 and 8. For example, referring to SEQ ID NO: 5 and FIG. 3, the "Xaa" at position 2 may be a tyrosine or a lysine. The generic sequences provide an appropriate cysteine skeleton for inter- or intramolecular disulfide bonding, and contain certain critical amino acids likely to influence the tertiary structure of the proteins. In addition, the "Xaa" at position 36 in SEQ ID NO: 4, or at position 41 in SEQ ID NO: 5, may be an additional cysteine, thereby encompassing the morphogenically-active sequences of OP-2 and OP-3.

In another embodiment, useful morphogens include those defined by SEQ ID NOS: 6 or 7, which are composite amino acid sequences of the following morphogens: human OP-1, human OP-2, human OP-3, human BMP-2, human BMP-3, human BMP-4, human BMP-5, human

BMP-6, human BMP-8, human BMP-9, human BMP-10, human BMP-11, *Drosophila* 60A, Xenopus Vg-1, sea urchin UNIVIN, human CDMP-1 (mouse GDF-5), human CDMP-2 (mouse GDF-6, human BMP-13), human CDMP-3 (mouse GDF-7, human BMP-12), mouse GDF-3, human GDF-1, mouse GDF-1, chicken DORSALIN, *Drosophila* dpp, *Drosophila* SCREW, mouse NODAL, mouse GDF-8, human GDF-8, mouse GDF-9, mouse GDF-10, human GDF-11, mouse GDF-11, human BMP-15, and rat BMP-3b. SEQ ID NO: 7 includes all of SEQ ID NO: 6 and also includes at its N-terminus the five amino acid sequence of SEQ ID NO: 9. SEQ ID NO: 6 accommodates the C-terminal six-cysteine skeleton, and SEQ ID NO: 7 accommodates the seven-cysteine skeleton. Positions that allow for alternative amino acids are represented by "Xaa". FIG. 4 shows the alternative amino acids for each "Xaa" position in SEQ ID NOS: 6, 7 and 9.

As noted above, certain preferred morphogen sequences useful in this invention have greater than 60% identity, preferably greater than 65% identity, with the amino acid sequence defining the preferred reference sequence of hOP-1. These particularly preferred sequences include allelic and phylogenetic variants of the OP-1 and OP-2 proteins, including the *Drosophila* 60A protein, as well as the closely related proteins BMP-5, BMP-6 and Vgr-1. Accordingly, in certain particularly preferred embodiments, useful morphogens include proteins comprising the generic amino acid sequence SEQ ID NO: 3 (referred to herein as "OPX"), which defines the seven-cysteine skeleton and accommodates the homologies between several identified variants of OP-1 and OP-2. Positions that allow for alternative amino acids are represented by "Xaa". FIG. 5 shows the alternative amino acids for each "Xaa" position in SEQ ID NO: 3.

In still another preferred embodiment, useful morphogens include those having an amino acid sequence encoded by a polynucleotide that hybridizes under high stringency conditions with DNA or RNA encoding a reference morphogen. Standard stringency conditions are well characterized in standard molecular biology texts. See generally MOLECULAR CLONING A LABORATORY MANUAL, (Sambrook *et al.*, eds., 1989); DNA CLONING, Vol. I & II (D.N. Glover ed., 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed., 1984); NUCLEIC ACID HYBRIDIZATION (B. D. Hames & S.J. Higgins eds. 1984); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984).

In another embodiment, morphogens useful in the invention include the soluble complex form comprising a mature morphogen dimer linked to a morphogen pro domain or a solubility-enhancing fragment thereof. A solubility-enhancing fragment is any N-terminal or

- 11 -

C-terminal fragment of a morphogen pro domain that forms a complex with the mature morphogen dimer and increases the solubility of the morphogen dimer. Preferably, the soluble complex comprises a morphogen dimer and two pro domain peptides. Morphogen soluble complex is described in published application WO 94/03600, incorporated by reference herein.

- 5 In yet another embodiment, useful morphogens include biologically active biosynthetic constructs, including novel biosynthetic morphogens and chimeric proteins designed using sequences from two or more known morphogens. See U.S. Patent No. 5,011,691, incorporated by reference herein (*e.g.*, COP-1, COP-3, COP-4, COP-5, COP-7, and COP-16).

II. FORMULATION AND DELIVERY CONSIDERATIONS

10 A. General Considerations

- Devices of the invention can be formulated using routine methods. All that is required is determination of the desired final concentration of osteogenic protein per device, keeping in mind that the delivered volume of device can be, but is not necessarily required to be, less than the volume at the defect site. Useful formulation methodologies include lyophilization of solubilized protein onto a calcium phosphate matrix. Useful protein solubilization solutions include acidic ethanol, urea, acidic buffers, and acetonitrile/trifluoroacetic acid solutions, and the like. See, for example, U.S. 5,266,683. The desired final concentration of protein will depend on the specific activity of the protein as well as the type, volume, and/or anatomical location of the defect. Proteins having lower specific activity also can be used to advantage. Additionally, the desired final concentration of protein can depend on the age, sex and/or overall health of the recipient. Typically, for a critical size bone segmental defect approximately at least 2.5 cm in length, 0.5-1.75 mg osteogenic protein has been observed using the standard device to induce bone formation sufficient to repair the gap. In the case of a non-critical size defect or a fresh fracture, approximately 0.1-0.5 mg protein has been observed using the standard osteogenic device to repair the defect. Optimization of dosages requires no more than routine experimentation and is within the skill level of one of ordinary skill in the art.
- 15
20
25

- Osteogenic devices and formulations are readily sterilized using standard procedures prior to implantation. For example, proteins conveniently can be filter-sterilized, *e.g.*, using a 0.22 micron filter. Matrix and/or carrier materials can be sterilized by exposure to chemicals, heat, or ionizing radiation. In addition, osteogenic devices and formulations can be terminally sterilized to
- 30

a sterility assurance level of 10^{-6} by exposure to ionizing radiation, for example, gamma or electron beam radiation. Useful dose ranges include within the range of about 0.5-4.0 megarads, preferably 2.0-3.5 megarads. See, for example, USSN 08/478,452 filed June 7, 1995, or WO 96/40297.

- 5 Practice of the invention will be still more fully understood from the following examples, which are presented herein for illustration only and should not be construed as limiting the invention in any way.

III. BIOASSAY

A. Bioassay of Osteogenic Activity: Endochondral Bone Formation and Related Properties

- 10 The art-recognized bioassay for bone induction described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80:6591-6595) and US Pat. No. 4,968,590, the disclosures of which are incorporated by reference herein, are useful to establish the efficacy of a given device or formulation. Briefly, the assay consists of depositing test samples in subcutaneous sites in recipient rats under ether anesthesia. A vertical incision (1 cm) is made under sterile conditions in
15 the skin over the thoracic region, and a pocket is prepared by blunt dissection. In certain circumstances, approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

- The sequential cellular reactions occurring at the heterotopic site are complex. The
20 multistep cascade of endochondral bone formation includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

- Successful implants exhibit a controlled progression through the stages of protein-induced
25 endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on about day one; (2) mesenchymal cell migration and proliferation on about days two and three; (3) chondrocyte appearance on about days five and six; (4) cartilage matrix formation on about day seven; (5) cartilage calcification on about day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on about days nine and ten; (7) appearance

of osteoblastic and bone remodeling on about days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on about day twenty-one. The timecourse of this process varies according to the matrix

5 Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Staining with toluidine blue or hemotoxylin/eosin clearly demonstrates the ultimate development of endochondral bone. Twelve day bioassays are sufficient to determine whether bone inducing activity is associated with the test sample.

10 Additionally, alkaline phosphatase activity can be used as a marker for osteogenesis. The enzyme activity can be determined spectrophotometrically after homogenization of the excised test material. The activity peaks at 9-10 days *in vivo* and thereafter slowly declines. Samples showing no bone development by histology should have no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the test samples are removed from the rat. For example, samples containing osteogenic protein at several levels of purity have been tested to determine the most effective dose/purity level, in order to seek a formulation which could be produced on an industrial scale. The results as measured by alkaline phosphatase activity level and histological evaluation can be represented as "bone forming units". One bone forming unit represents the amount of protein that is needed for half maximal bone forming activity on day 12. Additionally, dose curves can be constructed for bone inducing activity *in vivo* at each step of a purification scheme by assaying various concentrations of protein. Accordingly, the skilled artisan can construct representative dose curves using only routine experimentation.

B. Methods of Using a Hydroxyapatite Matrix for Delivery of Osteogenic Protein

25 An osteogenic device for use in methods of the present invention may comprise any combination of materials suitable to simulate bone growth. Ideally, such materials comprise a biocompatible matrix, implanted at the defect site, upon which new bone growth occurs; an osteogenic protein to stimulate optimal bone growth; and a concentration of calcium phosphate (e.g., hydroxyapatite) to modulate uniform ingrowth. For example, a preferred osteogenic device for use in methods according to the present invention comprises a bovine bone collagen matrix, a ceramic matrix, or a ceramic-collagen composite matrix. The matrix ideally is absorbed into new bone as bone formation takes place. The contents of the matrix may be varied in order to suit a

desired clinical application. For example, the source of the matrix may be varied, as may the osteogenic protein used. Numerous sources of bone matrix (*e.g.*, bovine bone, human bone, collagen, and composites) are known. *See, e.g.*, U.S. Patent Nos. 4,975,526, and 5,354,557, each of which is incorporated by reference herein.

5 Hydroxyapatite is made by reacting Tetracalcium phosphate and dicalcium phosphate anhydrous or dicalcium phosphate dihydrate in aqueous solution. Hydration of the reactants causes the cement to harden within about thirty minutes to form a microcrystalline lattice. Hydroxyapatite alone will be converted to bone when implanted in physical contact with existing bone near a defect site. However, when osteogenic protein is added, new bone growth, with
10 concomitant osteoconversion of hydroxyapatite, occurs even when there is no physical contact with existing bone. Osteogenic protein generally facilitates the osteoconversion on hydroxyapatite-based implants. Methods for preparing hydroxyapatite are reported, *inter alia*, in U.S. Patent Nos. Re. 33,161 and Re. 33,221, each of which is incorporated by reference herein.

 Improved methods according to the present invention are especially useful in the repair of
15 craniofacial damage or defects, or in other cosmetic surgery applications in which a uniform appearance of new bone is desired. For example, maxillary and mandibular atrophy is a recurrent problem in maxillofacial surgery. It is often difficult to obtain both the required functional results and to preserve aesthetic quality. As shown below, the amount and quality of bone formation in these bones may be affected by the choice of matrix.

20 The effects of hydroxyapatite on osteogenic protein induction of new bone growth were analyzed in a mandibular augmentation procedure. Bilateral pouches were created between the lateral aspect of the mandible and the masseteric muscle in 30 male Wistar rats. The bone surface was penetrated to induce bleeding, and one of six different carriers, each containing recombinant OP-1, were delivered to the defect site. The first two carriers were commercially-available
25 hydroxyapatite matrices (Algipore® and Bio-Oss®). Those were compared with commercially available preparations consisting of silicon granules (Ionogran®), bovine bone matrix (Osteovit®), or a collagen bone matrix. In each case, about 70 µg human recombinant OP-1 in acetate buffer was applied to the matrix. The contralateral side was used as a control in which the matrix contained only buffer.

Sequential post-operative labeling of the implant with fluorochromes was performed to enable visualization of bone ingrowth. The animals then were sacrificed at post-operative day 50, and undecalcified ground sections were processed for microradiography, fluorescent light evaluation, and histo-morphometry. Among the variables assessed were height of augmentation and amount of newly-formed bone. Only negligible bone apposition to the underlying mandibular bone was observed in control sites. While augmentation was observed in all OP-1 implanted sites, significant variations in structure and amount of newly-formed bone were found, depending on the matrix that was used. Results are presented in the table below. Mean augmentation height is provided in mm +/- SD. Bone density was determined as the area of newly-formed mineralized bone per total area of augmentation on 3 microradiographs from each specimen.

<u>Matrix</u>	<u>Mean Augmentation Height (mm)</u>	<u>Bone Density</u>
Algipore®	4.1 ± 0.8	51%
Bio-Oss® granules	5.2 ± 1.3	27%
Bio-Oss Spongiosa block®	5.1 ± 0.9	22%
Osteovit®	4.9 ± 1.2	42%
Ionogran®	3.2 ± 0.7	9.0%
Collagen Bone Matrix®	1.0 ± 0.9	84%

As shown in the table, augmentation height was significantly lower when either Ionogran® or collagen bone matrix was used as the matrix. The optimal combination of a desirable augmentation height and optimal density for cosmetic purposes was observed only in cases in which a hydroxyapatite matrix was used.

IV. FORMULATION OF OP-1/HA COMPOSITE DEVICES

A rat subcutaneous model was used to evaluate the clinical effectiveness of osteogenic protein/hydroxyapatite composite devices containing an optimal ratio of osteogenic protein to hydroxyapatite. A preferred osteogenic protein for use in methods of the invention is the osteogenic protein, OP-1. However, any osteogenic protein may be used in the manner taught herein.

- 16 -

Hydroxyapatite-based matrix formulations may take numerous forms. For example, they may be liquid solutions (e.g. 5% lactose, 20mM acetate/5% mannitol, pH 4.5), liquid gels (e.g. 5% CMC, 1% alginate), or putty pastes (e.g. CMC powder, gelatin powder). Porous hydroxyapatite blocks (discs) are preferred. Also preferred is a putty device comprising collagen matrix powders with Osteonics granules (0.6g CMC: 1.0 g HA). Bone formation was inhibited at low doses ($\leq 5 \mu\text{g}$), and was equivalent to controls at larger doses ($> 10 \mu\text{g}$). Also preferred are synthetic devices comprising 50% HA and 50% tricalcium phosphate.

A preferred OP-1/hydroxyapatite (HA) device was prepared by dry mixing OP-1 in a bone collagen device and HA in a ratio of 1:600 (OP-1/HA). The desired ratio of OP-1 to HA was achieved by mixing 2.5 mg OP-1 per gram of matrix, and then adding HA in a ratio of 60:40 (weight per weight) with respect to the matrix. The matrix was a bovine bone matrix, essentially as disclosed in U.S. Patent No. 5,354,557, incorporated by reference herein. The OP-1 was formulated essentially as disclosed in U.S. Patent No. 5,324,819, incorporated by reference herein.

Bilateral Subcutaneous pockets were created in the thorax of rats according to the protocol described in, incorporated by reference herein. A 25 mg aliquot comprising 10 mg of the OP-1 device (25 μg OP-1) was placed into each subcutaneous pocket. The rats were then sacrificed on day 3, 7, 12, 21, or 35. Implants were removed after sacrifice and fixed and demineralized in Boin's solution. The samples were then embedded in paraffin, sectioned and stained with Toluidine Blue.

About 90% of the OP-1/HA composite device comprising an optimal ratio (1:600) of OP-1 to HAC remained at day 7, with significant osteoconversion only on the periphery of the defect site. The time course for HA/OP-1 composite implants revealed a subsequent gradual conversion of the implant to endochondrial bone. Bone growth increased substantially by day 12 (50% of composite remaining) and day 21 (20% of composite remaining). There is no residual HA at day 35 post-implantation, and new bone growth is uniform in the defect site, with no evidence of annulus formation or the formation of any other non-uniform growth patterns.

When the OP-1 device was implanted without HA, the matrix disappeared at about day 21 and good bone and marrow were observed, but there was evidence of annulus formation at the

- 17 -

periphery of the ingrowth. HA disks coated with OP-1 produced no new bone growth after 12 days post-implantation.

The foregoing results demonstrate that HA/OP-1 composite devices incorporating an optimal ratio of osteogenic protein to hydroxyapatite produce uniform ingrowth of new bone, while ensuring complete resorption of HA.

A. Comparison of HA Materials

Two hydroxyapatite ceramic materials obtained from were evaluated as vehicles for delivery of an HA-OP-1 device for bone repair. Both materials were made from the same hydroxyapatite starting material, but one was sintered at 850 degrees Celsius and the other at 800 degrees Celsius. Both materials were in particle form with diameters ranging from about 212 μm to about 425 μm . Each of the hydroxyapatite materials was combined with varying amounts of OP-1 and the composites were evaluated for their ability to stimulate bone formation in rat subcutaneous sites. In general, about 60 mg of these hydroxyapatite occupies the same volume as about 25 mg of collagen.

Subcutaneous implants were made in rats as described above. Generally, bone formed into the implants with 10 μg of OP-1 per 60 mg HA.

The rate of release of OP-1 from collagen and hydroxyapatite into serum was next compared. About 62.5 μg of OP-1 was formulated with 25 mg of collagen or 60 mg of hydroxyapatite in 47.5% ethanol and 0.1% trifluoroacetic acid. After lyophilization, the devices were transferred to clean tubes and incubated with 1 ml of serum at 37 degrees Celsius. The serum was removed at the designated time points and replaced with fresh serum. Serum OP-1 levels were quantified by ELISA. It was determined that OP-1 release was similar from both the collagen and hydroxyapatite materials.

B. Effect of Co-Lyophilization of Op-1 and HA

Studies were done to assess the efficacy of implants comprising hydroxyapatite which had been co-lyophilized with OP-1 compared to a non-lyophilized formulation comprising hydroxyapatite particles mixed in an OP-1 solution comprising, in addition to OP-1, 20 mM acetate, pH 4.5, and 5% mannitol.

- 18 -

It was determined that either of the above formulations support adequate bone growth when 5 µg OP-1 was combined in 60 mg hydroxyapatite.

Next, the compatibility of OP-1 and hydroxyapatite particles sterilized by gamma radiation and the stability of an OP-1/HA composite sterilized by gamma radiation were evaluated:

- 5 An OP-1/HA device was formulated from 60 mg HA with 60 µg OP-1 by co-lyophilization from 47.5% ethanol/0.01% trifluoroacetic acid. The formulation was sterilized using 2.5-3.0 mrad of gamma radiation. A control device (no irradiation) was also made. The irradiated and control devices were eluted with Urea buffer, and analyzed by reverse phase HPLC. Approximately 30-40% of the OP-1 was lost upon irradiation, which is typical of the amount of
10 loss experienced when the collagen device is used. A Ross cell assay indicated that extracted OP-1 retained its biological activity.

V. CAT CRANIAL DEFECT MODEL

- An OP-1 bovine collagen device was mixed with hydroxyapatite cement HAC, wherein human osteogenic protein (OP-1) and HAC exist in a ratio of about 1:600 (OP-1: HAC) and was
15 used to repair induced cranial defects in cats. The composite device was essentially the same as the 1:600 device described above in Example 1. An OP-1/ HAC collagen composite device was compared to a control of pure HAC three months after implant using gross examination, computed tomography, and histologic/histometric techniques.

- Devices were implanted in the cats as follows. The parietal skull was exposed bilaterally
20 after a midline scalp incision, and the periosteal layer was separated from the skull as a flap. Using a high-speed cutting burr, two full-thickness craniotomies were created on the parietal skull, each about 2.5 cm in diameter, and symmetrical on either side of the midline. In each cat, pure HAC was placed into the area of the right craniotomy defect; whereas the left defect was replaced by the OP-1/HAC collagen device. After shaping of the external contour, implants were
25 allowed to solidify and the incisions were closed in layers.

 There were no wound infections, implant infections, or implant extrusions in any cat. The were sacrificed at 3 months post-operative. Skulls were removed and subsequently examined visually for shape, contour and overall appearance. The skulls were then examined by computed tomography with a bone algorithm in order to visualize the implanted areas. Next, the entire

- 19 -

outer calvarial portion of the skull, containing both implanted areas was removed and embedded in methylmethacrylate for undecalcified whole sections. Paragon- and Von Kossa-stained sections were obtained in order to differentiate HAC, bone, and osteoid components of bone. Histometric analysis was performed to determine the volume fraction of tissue components at the central area of the implant, the implant/bone interface, and the normal calvarial bone. In addition, the percent HAC resorption/replacement was determined by measuring the relative area of remnant implant over the entire implanted area.

A. Gross Histologic Examination

Upon visual examination of the removed skulls, the pure HAC implant appeared intact with shape, contour, and volume very close to that of the initially-applied cement. New bone ingrowth occurred only on the periphery of the defect site. The HAC implant was visible as a lighter color than the surrounding bone and was well-integrated with the surrounding bone. No volume change was apparent in the area of the implant.

In contrast, the OP-1/HAC collagen composite device implant was fully-replaced by new bone. There was no evidence of any remaining implant from the external surface or from the internal surfaces of the calcium. The shape, volume, and contour of the implanted area was preserved in the new bone.

B. Cross-Sectional Imaging

Coronal computerized tomography images of removed skulls revealed full-thickness, stable HAC implant on the HAC (right) side, with some peripheral induction of new bone. On the HAC/OP-1 device side, there was nearly-complete conversion of the composite implant, with the appearance of new lamellar bone. Again, the volume and shape of the new bone was well-preserved.

C. Histology

Paragon and Von Kossa staining revealed growth of new dense bone on the HAC/OP-1 side. The majority of the implant had been replaced by bone. Some remnant implant was seen as dark particles at the center of the implant. By measuring the relative cross-sectional area of the implant versus bone over the entire implanted area, it was calculated that about 93% (SD 3.7) of the composite implant was resorbed and replaced by new bone.

- 20 -

The foregoing data indicate that the composite implant of HAC/OP-1 accelerates the process of implant resorption and new bone formation. Pure HAC was successful only in reconstructing the cranial defect with osteointegration on the periphery of the implant site.

VI. USE OF HA/OP-1 DEVICE TO REPAIR BABOON CRANIAL DEFECTS

5 The efficacy of a single application of various doses of OP-1 absorbed onto sintered hydroxyapatite-based ceramic porous shaped form for osteointegration and bone regeneration in calvarial defects of adult baboons was next determined.

10 Sintered porous ceramic vehicles were made by heating hydroxyapatite slurries in stages and then sintering. The resulting material was a disc of porous sintered ceramic of about 25 mm in diameter and about 4 mm in thickness. Animals used in the experiments were four clinically-healthy adult male Chace baboons (*Papio ursinus*). The mean weight of all subjects was 28.7 kg (+/-2.3). Each subject had normal hematologic and biochemical profiles. The animals were obtained from the primate colony at Witwatersrand, Johannesburg, South Africa.

15 OP-1 was prepared by dissolving 0.0 (5 mM HCl control), 100, or 500 µg OP-1 in 500 µl of 5 mM Hcl. Sintered ceramic discs were prepared as described above. Absorption of the OP-1 into the ceramic carrier was carried out under sterile conditions. The OP-1 solutions were pipetted into the discs and air-dried.

20 Cranial defects were prepared in each of the animals using a craniotome. Two full-thickness defects, each about 25 mm in diameter, were prepared on each side of the calvaria. The defects were separated by about 3 cm of intervening calvarial bone. In each animal, 2 defects were implanted with sintered discs pretreated with 100 µg OP-1; one defect was treated with a device comprising 500 µg OP-1; and the fourth defect was implanted with a sintered porous disc with no OP-1 (control). Four weeks after implantation, the animals were sacrificed with an intravenous dose of pentobarbitone. Specimen blocks were cut along the sagittal third of the implanted discs and fixed in 10% neutral buffered formaldehyde. Specimens were then decalcified in a formic-hydrochloric acid mixture. Serial sections, each about 5 µm thick, were mounted after recording the position of the anterior and posterior interfaces of the defects with their corresponding calvarial margins. Sections were stained with Goldmer's trichome or with 0.1% toluidine blue in 30% ethanol. A calibrated Zeiss Integration Platte II (Zeiss) with 100 lattice
30 points was used to calculate, by point counting techniques, the fractional volume (in percent) of

- 21 -

the newly-formed bone. Sections were analyzed at a magnification of 40 times with a Zeiss graticule superimposed over five sources selected for histomorphometry and defined as follows: two anterior and posterior interfacial regions (AIF and PIF, respectively) two anterior and posterior internal regions (AIN and PIN, respectively) and a control region (CON). This technique allows the histomorphometric evaluation of the distribution of bone deposition across the hydroxyapatite substrata. Each source represented a field of 7.84 mm². Morphometry was performed on two sections per specimen, representing parasagittal levels approximately 5 mm apart from each other.

At sacrifice, control specimens showed fibrovascular tissue invasion across the porous spaces of the ceramic device, with some bone formation at the edges of the calvarial defects. There was no bone formation within the central or internal regions of the specimens. No significant resorption of the ceramic occurred in the control.

Porous ceramics pretreated with 100 µg OP-1 showed extensive bone formation within the porous spaces and in direct apposition with the substratum. There was prominent vascular invasion and the newly-formed bone had the features of trabecular woven bone extending into the porous spaces. Moreover, there was complete incorporation of the ceramic disc by newly-formed bone within the severed calvarial bone. Porous ceramics pretreated with 500 µg OP-1 showed bone formation only on the endocranial and pericranial aspects of the specimen, enveloping the ceramic substratum. The internal porous spaces of the ceramics were characterized by the presence of a rich vascular component, but bone formation was not observed. With both the 100 µg and the 500 µg samples, significant resorption of the ceramic material was observed when compared with the control implants. The results of histomorphologic analysis of the samples described above are shown in Table 2 below; wherein values are means of four control specimens and 12 OP-1 treated porous HA specimens.

TABLE 2

<u>Treatment</u>	<u>Control</u>	<u>100 µg OP-1</u>	<u>500 µg OP-1</u>
Volume fraction of induced bone (%)	0.7	32.6	23.6

- 22 -

The foregoing results indicate that the use of a ceramic carrier for high concentrations of OP-1 in the absence of a collagenous carrier results in bone formation mainly on the perennial and endocranial aspects of the specimens. With 500 µg OP-1, bone formation mainly enveloped the carrier and was rarely in contact with the substratum. In contrast, use of lower relative amounts of OP-1 (in the range of less than about 1:100 with respect to HAC) resulted in full, uniform induction of new bone.

VII. METAL IMPLANTS FOR GAP DEFECT REPAIR

In other embodiments of the invention, bone ingrowth in a defect is stimulated by implanting a metal implant in a bed of OP devices at the defect site. For example, a defect site, prepared by removing excess or necrotic bone tissue, is filled with an OP device. A metal implant, preferably coated with hydroxyapatite is then placed in the defect so that the OP device fills gap between the metal implant and the edges of the defect site. Preferably, an OP device comprises a morphogen, as herein described, in a suitable adjuvant, or in a collagen matrix, or another matrix as described herein. the following are several examples demonstrating this process.

A. Repair of gap defects using metal implant allograft therapy

Methods of the invention comprise repair of impaired bone stock, in, for example, revision endoprosthetic surgery, using impacted allograft bone chips. Adding the osteoinductive stimulation of osteogenic protein 1 (OP-1) to the osteoconductive effects of the allograft bone chips improves clinical outcome. OP-1 mixed into impacted allograft to improve bone formation and mechanical fixation of hydroxyapatite coated implants.

The effects of the OP-1 in Impacted allograft was evaluated in a canine model. Cylindrical hydroxyapatite-coated titanium alloy implants with an edged surface texture were used. The implants measured 4x9 mm and were inserted unloaded and bilaterally into the proximal humerus of 16 adult mongrel dogs surrounded by a 3 mm gap. Two different doses were tested in 8 animals each: (1) 325 µg OP-1 in 130 mg collagen matrix mixed into 1.3 g of allograft chips. (2) 65 µg OP-1 in 130 mg collagen matrix mixed into 1.3 g of allograft chips. The contralateral humerus were used for control in which the allograft were mixed with collagen matrix without OP-1 only. The dogs were sacrificed after 6 weeks. Bone ingrowth and bone formation in the gap was evaluated by quantitative histomorphometry and mechanical fixation of the implants were evaluated by push-out test.

Histomorphometry demonstrated an increase in pan-implant bone volume from 25.5% to 33.5% of total peri-implant gap volume. This increase was found for the 65 µg dose but not for the 325 µg dose. Bone ingrowth was relatively high for control groups (about 35%) and was not altered by OP-1 addition to the allograft. mechanical testing showed that sheer strength, stiffness and energy absorption were not increased for OP-1 simulated groups.

These data study demonstrate that the addition of OP-1 to impacted allograft increases bone formation around the implants using the lowest of the two doses tested. Mechanical fixation of the implants was not improved by OP-1 addition which could be explained by a similar lack of increased bone ingrowth in the groups receiving OP-1. These data indicate a clinical use of OP-1 for stimulation of bone formation in revision endoprosthetic surgery.

B. OP device in prosthetic surgery

In cementless endoprosthetic surgery gaps around implants impair bony fixation and clinical outcome. The following study shows that stimulation of bone healing with osteogenic factors improves clinical outcome of osteogenic prostheses.

Osteogenic protein (OP-1) has previously shown extensive *in vivo* osteoinductive properties in bone defect models, fracture models, and spine fusion models. However, little is known about morphogen's ability to enhance bony fixation of implants. Previously, only TGF-B has demonstrated stimulatory effects on bony fixation and bone formation when applied onto ceramic coated implants surrounded by a gap. The purpose of the present study was to determine if mechanical fixation of uncoated and hydroxyapatite coated implants is enhanced by applying OP-1 in a collagen carrier in a critical-sized, 3 mm, gap around the implants.

Enhancement of implant fixation with recombinant OP-1 was evaluated in a canine model approved by both the Danish and Stanford University control board for animal research. Cylindrical uncoated and hydroxyapatite coated titanium alloy implant (Ti6Al4V) (4x10 mm) with an edged surface texture were used. The implants were inserted unloaded bilaterally into both the medial and the lateral femoral condyles of 26 adult mongrel dogs. All implants were initially surrounded by a 3 mm gap. Eight dogs were included in each implant group. Three different groups for each type of implant were tested. (1) OP-1 device (325 µg OP-1 in 130 mg collagen matrix) (2) The collagen matrix without Op-1; (3) Empty gap. The OP-1 device and the collagen carrier was placed in the gap around the implants. The dogs were sacrificed after 8 weeks.

After sacrifice, mechanical fixation of the implants were evaluated by push-out test of a 3.5 mm thick specimen on an Instron universal testing machine. Shear strength, sheer stiffness

- 24 -

and energy absorption was determined. One way ANOVA and paired Students T-test were used. P values less than 0.05 were considered significant.

All dogs completed the study. Mechanical testing showed that shear strength, stiffness and energy absorption were significantly increased for OP-1 stimulated significant increased values above both control and collagen groups with respect to strength and stiffness, whereas for energy absorption OP-1 was only significantly different from the control group. For HA coated implants, the OP-1 group was significantly higher than both the control and collagen groups with respect to stiffness. Whereas for strength and energy absorption the OP-1 group was only significantly different from the control group. Collagen matrix was significantly higher than empty control for both implant types.

The present study demonstrates that the addition of OP-1 device increases mechanical fixation of both uncoated and hydroxyapatite coated implants. The strongest effects were found for uncoated implants where OP-1 device stimulated fixation to the same level as hydroxyapatite coated implants stimulated with the OP-1 device, since the empty control group no fixation was found. Interestingly, the collagen matrix by itself demonstrated a considerable stimulatory effect on fixation, probably due to an osteoconductive effect; whereas the collagen matrix captures stem-cells and other growth factors that will improve bone formation in the gap. The collagen matrix that results also emphasizes the importance of including such carrier controls in studies investigating systems and stimulative agents. For hydroxyapatite coated implants these effects were so dominant that no significant increase was demonstrated for hydroxyapatite coated implants with OP-1 device compared to hydroxyapatite coated implants with the collagen carrier alone, although a 40% increase was found. The study also showed that hydroxyapatite coating alone can bridge a gap of 3 mm in 6 weeks to provide some fixation, but that adding the OP-1 device strongly enhances bone formation to provide implant fixation in the range of 3 MPa regardless of whether uncoated or HA coated implants are used. These data are interesting for the use of OP-1 for stimulation of bony ingrowth in primary cements endoprosthetic surgery since OP-1 device was shown to enhance mechanical strength for the bone- implant interface of both uncoated and HA coated implants.

C. Hydroxyapatite-coated metal implants

Early incorporation of bone allograft material is of great importance. OP-1 (BMP-7) further enhances bone incorporation around implants, and Pro-Osteon 200 is an alternative to bone allograft.

- 25 -

The purpose of this study was to investigate whether OP-1 device in combination with bone allograft improves the early fixation of implants compared to the allograft alone. We also compared allograft to Pro-Osteon with and without OP-1.

Unloaded cylindrical titanium implants (5-10mm) coated with hydroxyapatite were randomly inserted in the medial and lateral femoral condyles of 6 labrador dogs described in sabelle, et al. Clin Ortho. 274: 283-293 (1992), incorporated by reference herein. A cavity of 11 mm in diameter was created by hand-drilling leaving a gap of 3 mm (0.75cc volume) around the implant. The implant was secured by a footplate and after grafting the gap, a top washer and a screw.

The gaps around the implants were filled according to the following treatment groups: Group 1: Allograft, group 2 Pro-Osteon, group 3: Allograft + OP-1 device, group 4: Pro-Osteon+OP-1 device. Allograft was harvested from a dog not included in the study, frozen at -80°C, thawed and milled in an operating room with laminar air flow. The amount of Pro-Osteon and allograft was standardized by weight. OP-1 was delivered in a device with 2.5 mg recombinant OP-1 in 1 gram bovine type 1 collagen, the concentration of OP-1 in the present study was 300 µg Op-1 in 120 mg collagen carrier. The bone substitute utilized was Pro-Osteon 200 (Interpore, Irvine US) corraline hydroxyapatite granules which has a porous microstructure similar to cortical bone. This product is a non- osteogenic void filler approved by the FDA for metaphyseal defects.

Dogs were sacrificed after 3 weeks and push-out and mechanical fixation was evaluated by a push-out test performed on and Instron Universal testing machine. Ultimate shear strength (MPa), apparent shear stiffness (MPa/mm) and energy absorption (3/mm²) were determined blindly from load displacement curves.

Statistical data are presented as mean values and standard error of mean. An unpaired t-test was used. (P-values less than 0.05 (two-tailed) were considered significant.) Push-out tests showed, that the OP-1 device enhanced fixation of Pro-Osteon by 900%. No significant differences were found between Pro-Osteon +OP-1 and allograft with or without OP-1, but all three groups had significantly better mechanical parameters compared to the Pro-Osteon group.

Implants treated with bone allograft were much stronger fixated than implants treated with Pro-Osteon alone. However in combination with OP-1, Pro-osteon treated implants were equally fixed compared to the allograft group.

The fact the OP-1 did not improve the fixation of the allograft group indicates that the allograft is a superior gap filling material around non cemented implants compared to Pro-Osteon. on the

- 27 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: David Rueger and Marjorie Tucker
- (ii) TITLE OF INVENTION: COMPOSITIONS FOR MORPHOGEN-INDUCED OSTEOGENESIS
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: CREATIVE BIOMOLECULES, INC.
 - (B) STREET: 45 SOUTH STREET
 - (C) CITY: HOPKINTON
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 01748
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Thomas C. Meyers
 - (B) REGISTRATION NUMBER: 36,989
 - (C) REFERENCE/DOCKET NUMBER: CRP-112
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 248-7000
 - (B) TELEFAX: (617) 248-7100

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1822 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: HOMO SAPIENS
 - (F) TISSUE TYPE: HIPPOCAMPUS
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 49..1341
 - (C) IDENTIFICATION METHOD: experimental
 - (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
- /product= "OP1"
 /evidence= EXPERIMENTAL
 /standard_name= "OP1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

GGTGC GGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG      57
                                         Met His Val
                                         1

CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA      105
Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala
      5              10              15

CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC      153

```

- 28 -

Pro 20	Leu	Phe	Leu	Leu	Arg 25	Ser	Ala	Leu	Ala	Asp 30	Phe	Ser	Leu	Asp	Asn 35	
GAG	GTG	CAC	TCG	AGC	TTC	ATC	CAC	CGG	CGC	CTC	CGC	AGC	CAG	GAG	CGG	201
Glu	Val	His	Ser	Ser 40	Phe	Ile	His	Arg	Arg 45	Leu	Arg	Ser	Gln	Glu 50	Arg	
CGG	GAG	ATG	CAG	CGC	GAG	ATC	CTC	TCC	ATT	TTG	GGC	TTG	CCC	CAC	CGC	249
Arg	Glu	Met	Gln	Arg 55	Glu	Ile	Leu	Ser 60	Ile	Leu	Gly	Leu	Pro 65	His	Arg	
CCG	CGC	CCG	CAC	CTC	CAG	GGC	AAG	CAC	AAC	TCG	GCA	CCC	ATG	TTC	ATG	297
Pro	Arg	Pro 70	His	Leu	Gln	Gly	Lys 75	His	Asn	Ser	Ala	Pro 80	Met	Phe	Met	
CTG	GAC	CTG	TAC	AAC	GCC	ATG	GCG	GTG	GAG	GAG	GGC	GGC	GGG	CCC	GGC	345
Leu	Asp 85	Leu	Tyr	Asn	Ala	Met 90	Ala	Val	Glu	Glu 95	Gly	Gly	Gly	Pro	Gly	
GGC	CAG	GGC	TTC	TCC	TAC	CCC	TAC	AAG	GCC	GTC	TTC	AGT	ACC	CAG	GGC	393
Gly	Gln	Gly	Phe	Ser	Tyr 105	Pro	Tyr	Lys	Ala	Val 110	Phe	Ser	Thr	Gln	Gly 115	
CCC	CCT	CTG	GCC	AGC	CTG	CAA	GAT	AGC	CAT	TTC	CTC	ACC	GAC	GCC	GAC	441
Pro	Pro	Leu	Ala	Ser 120	Leu	Gln	Asp	Ser	His 125	Phe	Leu	Thr	Asp 130	Ala	Asp	
ATG	GTC	ATG	AGC	TTC	GTC	AAC	CTC	GTG	GAA	CAT	GAC	AAG	GAA	TTC	TTC	489
Met	Val	Met	Ser 135	Phe	Val	Asn	Leu	Val 140	Glu	His	Asp	Lys	Glu 145	Phe	Phe	
CAC	CCA	CGC	TAC	CAC	CAT	CGA	GAG	TTC	CGG	TTT	GAT	CTT	TCC	AAG	ATC	537
His	Pro	Arg 150	Tyr	His	His	Arg	Glu 155	Phe	Arg	Phe	Asp	Leu 160	Ser	Lys	Ile	
CCA	GAA	GGG	GAA	GCT	GTC	ACG	GCA	GCC	GAA	TTC	CGG	ATC	TAC	AAG	GAC	585
Pro	Glu	Gly	Glu	Ala	Val 170	Thr	Ala	Ala	Glu	Phe	Arg 175	Ile	Tyr	Lys	Asp	
TAC	ATC	CGG	GAA	CGC	TTC	GAC	AAT	GAG	ACG	TTC	CGG	ATC	AGC	GTT	TAT	633
Tyr	Ile	Arg	Glu	Arg	Phe 185	Asp	Asn	Glu	Thr	Phe 190	Arg	Ile	Ser	Val	Tyr 195	
CAG	GTG	CTC	CAG	GAG	CAC	TTG	GGC	AGG	GAA	TCG	GAT	CTC	TTC	CTG	CTC	681
Gln	Val	Leu	Gln 200	Glu	His	Leu	Gly	Arg 205	Glu	Ser	Asp	Leu	Phe 210	Leu	Leu	
GAC	AGC	CGT	ACC	CTC	TGG	GCC	TCG	GAG	GAG	GGC	TGG	CTG	GTG	TTT	GAC	729
Asp	Ser	Arg 215	Thr	Leu	Trp	Ala	Ser 220	Glu	Gly	Gly	Trp	Leu	Val 225	Phe	Asp	
ATC	ACA	GCC	ACC	AGC	AAC	CAC	TGG	GTG	GTC	AAT	CCG	CGG	CAC	AAC	CTG	777
Ile	Thr 230	Ala	Thr	Ser	Asn	His	Trp 235	Val	Val	Asn	Pro 240	Arg	His	Asn	Leu	
GGC	CTG	CAG	CTC	TCG	GTG	GAG	ACG	CTG	GAT	GGG	CAG	AGC	ATC	AAC	CCC	825
Gly	Leu	Gln	Leu	Ser 245	Val	Glu	Thr 250	Leu	Asp	Gly 255	Gln	Ser	Ile	Asn	Pro	
AAG	TTG	GCG	GGC	CTG	ATT	GGG	CGG	CAC	GGG	CCC	CAG	AAC	AAG	CAG	CCC	873
Lys	Leu	Ala	Gly	Leu 265	Ile	Gly	Arg	His	Gly 270	Pro	Gln	Asn	Lys	Gln 275	Pro	
TTC	ATG	GTG	GCT	TTC	TTC	AAG	GCC	ACG	GAG	GTC	CAC	TTC	CGC	AGC	ATC	921
Phe	Met	Val	Ala 280	Phe	Phe	Lys	Ala	Thr 285	Glu	Val	His	Phe	Arg 290	Ser	Ile	
CGG	TCC	ACG	GGG	AGC	AAA	CAG	CGC	AGC	CAG	AAC	CGC	TCC	AAG	ACG	CCC	969
Arg	Ser	Thr 295	Gly	Ser	Lys	Gln	Arg 300	Ser	Gln	Asn	Arg	Ser 305	Lys	Thr	Pro	
AAG	AAC	CAG	GAA	GCC	CTG	CGG	ATG	GCC	AAC	GTG	GCA	GAG	AAC	AGC	AGC	1017
Lys	Asn	Gln	Glu	Ala	Leu	Arg	Met 315	Ala	Asn	Val	Ala 320	Glu	Asn	Ser	Ser	
AGC	GAC	CAG	AGG	CAG	GCC	TGT	AAG	AAG	CAC	GAG	CTG	TAT	GTC	AGC	TTC	1065

- 30 -

```

Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr
    115          120          125
Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys
    130          135          140
Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu
    145          150          155          160
Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile
    165          170          175
Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile
    180          185          190
Ser Val Tyr Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu
    195          200          205
Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu
    210          215          220
Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg
    225          230          235          240
His Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser
    245          250          255
Ile Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn
    260          265          270
Lys Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe
    275          280          285
Arg Ser Ile Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser
    290          295          300
Lys Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu
    305          310          315          320
Asn Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr
    325          330          335
Val Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu
    340          345          350
Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn
    355          360          365
Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His
    370          375          380
Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln
    385          390          395          400
Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
    405          410          415
Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
    420          425          430

```

(2) INFORMATION FOR SEQ ID NO.3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /label= OPX

/note= "wherein each Xaa is independently selected from a group

- 29 -

Ser	Asp	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val	Ser	Phe	
325						330					335					
CGA	GAC	CTG	GGC	TGG	CAG	GAC	TGG	ATC	ATC	GCG	CCT	GAA	GGC	TAC	GCC	1113
Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala	
340					345					350					355	
GCC	TAC	TAC	TGT	GAG	GGG	GAG	TGT	GCC	TTC	CCT	CTG	AAC	TCC	TAC	ATG	1161
Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asn	Ser	Tyr	Met	
				360					365					370		
AAC	GCC	ACC	AAC	CAC	GCC	ATC	GTG	CAG	ACG	CTG	GTC	CAC	TTC	ATC	AAC	1209
Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu	Val	His	Phe	Ile	Asn	
			375					380					385			
CCG	GAA	ACG	GTG	CCC	AAG	CCC	TGC	TGT	GCG	CCC	ACG	CAG	CTC	AAT	GCC	1257
Pro	Glu	Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln	Leu	Asn	Ala	
			390				395					400				
ATC	TCC	GTC	CTC	TAC	TTC	GAT	GAC	AGC	TCC	AAC	GTC	ATC	CTG	AAG	AAA	1305
Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys	Lys	
405						410					415					
TAC	AGA	AAC	ATG	GTG	GTC	CGG	GCC	TGT	GGC	TGC	CAC	TAGCTCCTCC				1351
Tyr	Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly	Cys	His					
420					425					430						
GAGAATTCAG	ACCCTTTGGG	GCCAAGTTTT	TCTGGATCCT	CCATTGCTCG	CCTTGCCAG											1411
GAACCAGCAG	ACCAACTGCC	TTTTGTGAGA	CCTTCCCTC	CCTATCCCCA	ACTTTAAAGG											1471
TGTGAGAGTA	TTAGGAAACA	TGAGCAGCAT	ATGGCTTTTG	ATCAGTTTTT	CAGTGGCAGC											1531
ATCCAATGAA	CAAGATCCTA	CAAGCTGTGC	AGGCAAAACC	TAGCAGGAAA	AAAAACAAC											1591
GCATAAGAA	AAATGGCCGG	GCCAGGTCAT	TGGCTGGGAA	GTCTCAGCCA	TGCACGGACT											1651
CGTTTCCAGA	GGTAATTATG	AGCGCTACC	AGCCAGGCCA	CCCAGCCGTG	GGAGGAAGGG											1711
GGCGTGGCAA	GGGGTGGGCA	CATTGGTGTC	TGTGCGAAAG	GAAAATTGAC	CCGGAAGTTC											1771
CTGTAATAAA	TGTCACAATA	AAACGAATGA	ATGAAAAAAA	AAAAAAAAAA	A											1822

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 431 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	His	Val	Arg	Ser	Leu	Arg	Ala	Ala	Ala	Pro	His	Ser	Phe	Val	Ala	
1				5					10					15		
Leu	Trp	Ala	Pro	Leu	Phe	Leu	Leu	Arg	Ser	Ala	Leu	Ala	Asp	Phe	Ser	
		20						25					30			
Leu	Asp	Asn	Glu	Val	His	Ser	Ser	Phe	Ile	His	Arg	Arg	Leu	Arg	Ser	
		35					40					45				
Gln	Glu	Arg	Arg	Glu	Met	Gln	Arg	Glu	Ile	Leu	Ser	Ile	Leu	Gly	Leu	
	50					55					60					
Pro	His	Arg	Pro	Arg	Pro	His	Leu	Gln	Gly	Lys	His	Asn	Ser	Ala	Pro	
	65				70				75						80	
Met	Phe	Met	Leu	Asp	Leu	Tyr	Asn	Ala	Met	Ala	Val	Glu	Glu	Gly	Gly	
			85					90						95		
Gly	Pro	Gly	Gly	Gln	Gly	Phe	Ser	Tyr	Pro	Tyr	Lys	Ala	Val	Phe	Ser	
		100					105						110			

- 31 -

of one or more specified amino acids as defined in the specification."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Cys Xaa Xaa His Glu Leu Tyr Val Ser Phe Xaa Asp Leu Gly Trp Xaa
1      5      10      15
Asp Trp Xaa Ile Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly
20      25      30
Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala
35      40      45
Ile Xaa Gln Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys
50      55      60
Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa
65      70      75      80
Asp Xaa Ser Xaa Asn Val Ile Leu Xaa Lys Xaa Arg Asn Met Val Val
85      90      95
Xaa Ala Cys Gly Cys His
100

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..97
- (D) OTHER INFORMATION: /label= Generic-Seq-7

/note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa Xaa Xaa Xaa Xaa
1      5      10      15
Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Pro
20      25      30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa Xaa
35      40      45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Pro
50      55      60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa
65      70      75      80
Val Xaa Leu Xaa Xaa Xaa Xaa Met Xaa Val Xaa Xaa Cys Xaa Cys
85      90      95
Xaa

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:

- 32 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /label= Generic-Seq-8

/note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Cys Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa
1          5          10          15
Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly
20          25          30
Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala
35          40          45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50          55          60
Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
65          70          75          80
Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val
85          90          95
Xaa Xaa Cys Xaa Cys Xaa
100

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..97

(D) OTHER INFORMATION: /label= Generic-Seq-9

/note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1          5          10          15
Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Gly Xaa Cys Xaa Xaa Xaa
20          25          30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35          40          45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro
50          55          60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65          70          75          80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
85          90          95

```

- 33 -

Xaa

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /label= Generic-Seq-10

/note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1      5      10      15
Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Gly
20      25      30
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35      40      45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50      55      60
Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
65      70      75      80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
85      90      95
Xaa Xaa Cys Xaa Cys Xaa
100

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..5

(D) OTHER INFORMATION: /note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Cys Xaa Xaa Xaa Xaa
1      5

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid

- 34 -

(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Protein
(B) LOCATION: 1..5
(D) OTHER INFORMATION: /note= "wherein each Xaa is
independently selected from a group of one or more specified
amino acids as defined in the specification"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Cys Xaa Xaa Xaa Xaa
1 5

What is claimed is:

- 1 1. A method for producing new bone growth at bone defect site in a mammal, the method
2 comprising the step of:
3 implanting in a defect site a calcium phosphate matrix comprising at least one osteogenic
4 protein.
- 1 2. The method of claim 1, wherein said calcium phosphate matrix is a hydroxyapatite matrix.
- 1 3. The method of claim 1, wherein said osteogenic protein is a dimeric protein that comprises
2 an amino acid sequence selected from the group consisting of:
3 (a) a sequence having at least 70% homology with the C-terminal seven-cysteine
4 skeleton of human OP-1, residues 38-139 of SEQ ID NO: 5, and
5 (b) Generic Sequence 6, SEQ ID NO: 31; and
6 wherein said morphogen stimulates endochondral bone formation in an in vivo bone
7 assay.
- 1 4. The method of claim 1, wherein said osteogenic protein is a dimeric protein that comprises
2 an amino acid sequence selected from the group consisting of:
3 (a) a sequence having greater than 60% amino acid sequence identity with the
4 C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID
5 NO: 5, and
6 (b) OPX sequence defined by SEQ. ID No: 29; and
7 wherein said osteogenic protein stimulates endochondral bone formation in an in vivo
8 bone assay.
- 1 5. The method of claim 1, wherein said osteogenic protein is selected from the group
2 consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1,
3 BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6.
- 1 6. The method of claim 1, wherein said osteogenic protein is a conservative substitution
2 variant of a morphogen selected from the group consisting of human OP-1, mouse OP-1,

3 human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3,
4 BMP5, and BMP6.

1 7. A method for producing new bone growth at a defect site in a mammal, the method
2 comprising the step of:
3 implanting an osteogenic device in said defect site, the osteogenic device comprising an
4 osteogenic protein and a biocompatible matrix; wherein said biocompatible matrix comprises
5 calcium phosphate in an amount such that the ratio of calcium phosphate to said osteogenic
6 protein is sufficient to produce uniform ingrowth of new bone in said defect site.

7

1 8. The method of claim 7, wherein said calcium phosphate is hydroxyapatite.

1 9. The method of claim 7, wherein said ratio of calcium phosphate to osteogenic protein is
2 less than about 1:10,000.

1 10. The method of claim 7, wherein said ratio of calcium phosphate to osteogenic protein is
2 about 1:2000.

1 11. The method of claim 7, wherein said ratio is about 1:600.

1 12. The method according to claim 7, wherein said ratio is 1:700.

1 13. The method according to claim 7, wherein said ratio is 1:500.

1 14. The method according to claim 7, wherein said ratio is 1:1000.

1 15. A method for stimulating new bone growth at a defect site in a mammalian bone,
2 comprising the step of:
3 introducing calcium phosphate and osteogenic protein to a defect site in a ratio sufficient
4 to produce uniform ingrowth of new bone.

1 16. The method of claim 15, wherein said calcium phosphate is hydroxyapatite.

1 17. The method of claim 16, wherein said hydroxyapatite is a sintered hydroxyapatite.

1 18. The method of claim 15, wherein said ratio is less than about 1:100.

1 19. The method of claim 15, wherein said ratio is about 1:500

1 20. The method of claim 15, wherein said ratio is about 1:600.

- 1 21. The method of claim 15, wherein said ratio is about 1:700.
- 1 22. A method for inducing uniform calcium resorption in a bone defect site, the method
2 comprising the steps of:
3 implanting in said defect site an osteogenic device comprising a biocompatible matrix,
4 calcium phosphate, and an osteogenic protein; wherein said osteogenic protein and said
5 calcium phosphate are present in said device in a ratio of less than about 1:1000.
- 1 23. The method of claim 22, wherein said calcium phosphate is hydroxyapatite.
- 1 24. The method of claim 22, wherein said ratio is about 1:500.
- 1 25. The method of claim 22, wherein said ratio is about 1:600.
- 1 26. The method of claim 22, wherein said ratio is about 1:700.
- 1 27. A method for promoting bone ingrowth in a defect site, the method comprising the steps
2 of:
3 (a) implanting in a defect site a metal implant; and
4 (b) surrounding said implant with a composition comprising a morphogen selected for the
5 groups consisting of:
6 (1) a morphogen having at least 70% amino acid homology with the C-terminal, seven-
7 cysteine domain of human OP-1, SEQ ID NO: and
8 (2) a morphogen having at least 60% amino acid identity with the C-terminal, seven-
9 cysteine domain of human OP-1, SEQ ID NO: .
- 1 28. The method of claim 27, wherein said metal implant is a titanium implant.
- 1 29. The method of claim 27, wherein said metal implant is coated with hydroxyapatite.
- 1 30. The method of claim 27, wherein said morphogen is OP-1.
- 1 31. The method of claim 27, wherein said morphogen is selected from the group consists of
2 BMP2, BMP4, BMP5, and BMP6.
- 1 32. The method of claim 27, wherein said composition further comprises a collagen matrix.
- 1 33. The method of claim 27, wherein said composition further comprises a carboxy methyl
2 cellulose matrix.
- 1 34. The method of claim 27 wherein said composition further comprises a calcium phosphate
2 matrix.
- 1 35. The method of claim 34, wherein said calcium phosphate matrix is a hydroxyapatite matrix.

hOP-1	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val
mOP-1
hOP-2	...	Arg	Arg
mOP-2	...	Arg	Arg
mOP-3	...	Arg	Arg
DPP	...	Arg	Arg	...	Ser
Vgl	Lys	Arg	His
Vgr-1	Gly
CBMP-2A	Arg	...	Pro
CBMP-2B	...	Arg	Arg	...	Ser
BMP3	...	Ala	Arg	Arg	Tyr	...	Lys	...
GDF-1	...	Arg	Ala	Arg	Arg
60A	...	Gln	Met	Glu	Thr
BMP5
BMP6	...	Arg
	1				5			

FIG. 1A

FIG. 1B

FIG. 10

hOP-1	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala
mOP-1
hOP-2	Ser
mOP-2
mOP-3	Ala	Ile
DPP	His	...	Lys	...	Pro
Vgl	...	Asn	Tyr	Pro
Vgr-1	...	Asn	Asp	Ser
CBMP-2A	...	Phe	His	...	Glu	...	Pro
CBMP-2B	...	Phe	His	...	Asp	...	Pro
BMP3	Ser	...	Ala	...	Gln
GDF-1	...	Asn	Gln	...	Gln
60A	...	Phe	Ser	Asn
BMP5	...	Phe	Asp	Ser
BMP6	...	Asn	Asp	Ser
				30					35

FIG. 1D

hOP-1	Phe	Pro	Leu	Asn	Ser	Tyr	Met	Asn	Ala
mOP-1
hOP-2	Asp	...	Cys
mOP-2	Asp	...	Cys
mOP-3	Tyr	Cys	Ser
DPP	Ala	Asp	His	Phe	...	Ser
Vgl	Tyr	Thr	Glu	Ile	Leu	...	Gly
Vgr-1	Ala	His
CBMP-2A	Ala	Asp	His	Leu	...	Ser
CBMP-2B	Ala	Asp	His	Leu	...	Ser
GDF-1	Leu	...	Val	Ala	Leu	Ser	Gly	Ser**	...
BMP3	Met	Pro	Lys	Ser	Leu	Lys	Pro
60A	Ala	His
BMP5	Ala	His	Met
BMP6	Ala	His	Met

40

FIG. 1E

hOP-1	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu
mOP-1
hOP-2	Leu	...	Ser	...
mOP-2	Leu	...	Ser	...
mOP-3	Thr	Met	...	Ala	...
DPP	Val
Vgl	Ser	Leu
Vgr-1
CBMP-2A
CBMP-2B
BMP3	Ser	Thr	Ile	...	Ser	Ile
GDF-1	Leu	Val	Leu	Arg	Ala	...
60A
BMP5
BMP6
	45					50			

FIG. 1F

hOP-1	Val	His	Phe	Ile	Asn	Pro	Glu	Thr	Val
mOP-1	Asp
hOP-2	...	His	Leu	Met	Lys	...	Asn	Ala	...
mOP-2	...	His	Leu	Met	Lys	...	Asp	Val	...
mOP-3	Leu	Met	Lys	...	Asp	Ile	Ile
DPP	...	Asn	Asn	Asn	Gly	Lys	...
Vgl	Ser	...	Glu	Asp	Ile
Vgr-1	Val	Met	Tyr	...
CBMP-2A	...	Asn	Ser	Val	...	Ser	...	Lys	Ile
CBMP-2B	...	Asn	Ser	Val	...	Ser	...	Ser	Ile
BMP3	...	Arg	Ala**	Gly	Val	Val	Pro	Gly	Ile
GDF-1	Met	...	Ala	Ala	Ala	...	Gly	Ala	Ala
60A	Leu	Leu	Glu	...	Lys	Lys	...
BMP5	Leu	Met	Phe	...	Asp	His	...
BMP6	Leu	Met	Tyr	...
		55					60		

FIG. 1G

hOP-1	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
mOP-1
hOP-2	Ala	Lys
mOP-2	Ala	Lys
mOP-3	Val	Val	Glu
DPP	Ala	Val
Vgl	...	Leu	Val	Lys
Vgr-1	Lys
CBMP-2A	Ala	Val	Glu
CBMP-2B	Ala	Val	Glu
BMP3	...	Glu	Val	...	Glu	Lys
GDF-1	Asp	Leu	Val	...	Ala	Arg
60A	Arg
BMP5	Lys
BMP6	Lys
									70
									65

FIG. 1H

hOP-1	Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe
mOP-1
hOP-2	...	Ser	...	Thr	Tyr
mOP-2	...	Ser	...	Thr	Tyr
mOP-3	...	Ser	Leu	Tyr
Vgl	Met	Ser	Pro	Met	...	Phe	Tyr
Vgr-1	Val
DPP	...	Asp	Ser	Val	Ala	Met	Leu
CBMP-2A	...	Ser	Met	Leu
CBMP-2B	...	Ser	Met	Leu
BMP3	Met	Ser	Ser	Leu	...	Ile	...	Phe	Tyr
GDF-1	...	Ser	Pro	Phe	...
60A	...	Gly	...	Leu	Pro	His
BMP5
BMP6
				75					80

FIG. II

hOP-1	Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys
mOP-1
hOP-2	...	Ser	...	Asn	Arg
mOP-2	...	Ser	...	Asn	Arg
mOP-3	...	Arg	Asn	Asn	Arg
DPP	Asn	...	Gln	...	Thr	...	Val
Vgl	...	Asn	Asn	Asp	Val	...	Arg
Vgr-1	Asn
CBMP-2A	...	Glu	Asn	Glu	Lys	...	Val
CBMP-2B	...	Glu	Tyr	Asp	Lys	...	Val
BMP3	...	Glu	Asn	Lys	Val
GDF-1	...	Asn	...	Asp	Val	...	Arg
60A	Leu	Asn	Asp	Glu	Asn
BMP5
BMP6	Asn

85

FIG. 1J

10/19

hOP-1	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg
mOP-1
hOP-2	...	His	Lys
mOP-2	...	His	Lys
mOP-3	Arg	Glu	Gln
DPP	Asn	...	Gln	Glu	...	Thr	...	Val
Vgl	His	...	Glu	Ala	...	Asp
Vgr-1
CBMP-2A	Asn	...	Gln	Asp	Glu
CBMP-2B	Asn	...	Gln	Glu	Glu
BMP3	Val	...	Pro	Thr	...	Glu
GDF-1	Gln	...	Glu	Asp	Asp
60A	Ile	...	Lys
BMP5
BMP6	Trp
	90					95		

FIG. 1K

hOP-1	Ala	Cys	Gly	Cys	His
mOP-1
hOP-2
mOP-2
mOP-3
DPP	Gly	Arg
Vgl	Glu	Arg
Vgr-1
CBMP-2A	Gly	Arg
CBMP-2B	Gly	Arg
BMP3	Ser	...	Ala	...	Arg
GDF-1	Glu	Arg
60A	Ser
BMP5	Ser
BMP6
			100		

FIG. 1L

**Between residues 56 and 57 of BMP3 is a Val residue;
between residues 43 and 44 of GDF-1 lies the amino acid
sequence Gly-Gly-Pro-Pro.

FIG. 1M

13/19

AMINO ACID POSITION			
SEQ. ID NO: 4	SEQ ID NO: 5	SEQ ID NO: 8	Xaa=
	2	2	Lys, Arg, Ala, or Gln
	3	3	Lys, Arg, or Met
	4	4	His, Arg, or Gln
	5	5	Glu, Ser, His, Gly, Arg, Pro, Thr, or Tyr
2	7		Tyr or Lys
3	8		Val or Ile
4	9		Ser, Asp, or Glu
6	11		Arg, Gln, Ser, Lys, or Ala
7	12		Asp or Glu
8	13		Leu, Val, or Ile
11	16		Gln, Leu, Asp, His, Asn, or Ser
12	17		Asp, Arg, Asn, or Glu
13	18		Trp or Ser
14	19		Ile or Val
15	20		Ile or Val
16	21		Ala or Ser
18	23		Glu, Gln, Leu, Lys, Pro, or Arg
19	24		Gly or Ser
20	25		Tyr or Phe
21	26		Ala, Ser, Asp, Met, His, Gln, Leu, or Gly
23	28		Tyr, Asn, or Phe
26	31		Glu, His, Tyr, Asp, Gln, Ala, or Ser
28	33		Glu, Lys, Asp, Gln, or Ala
30	35		Ala, Ser, Pro, Gln, Ile, or Asn
31	36		Phe, Leu, or Tyr
33	38		Leu, Val, or Met
34	39		Asn, Asp, Ala, Thr, or Pro
35	40		Ser, Asp, Glu, Leu, Ala, or Lys
36	41		Tyr, Cys, His, Ser, or Ile
37	42		Met, Phe, Gly, or Leu
38	43		Asn, Ser, or Lys
39	44		Ala, Ser, Gly, or Pro
40	45		Thr, Leu, or Ser
44	49		Ile, Val, or Thr
45	50		Val, Leu, Met, or Ile
46	51		Gln or Arg
47	52		Thr, Ala, or Ser
48	53		Leu or Ile
49	54		Val or Met
50	55		His, Asn, or Arg
51	56		Phe, Leu, Asn, Ser, Ala, or Val
52	57		Ile, Met, Asn, Ala, Val, Gly, or Leu
53	58		Asn, Lys, Ala, Glu, Gly, or Phe
54	59		Pro, Ser, or Val

FIG. 2A

AMINO ACID POSITION			
SEQ. ID NO: 4	SEQ ID NO: 5	SEQ ID NO: 8	Xaa=
55	60		Glu, Asp, Asn, Gly, Val, Pro, or Lys
56	61		Thr, Ala, Val, Lys, Asp, Tyr, Ser, Gly, Ile, or His
57	62		Val, Ala, or Ile
58	63		Pro or Asp
59	64		Lys, Leu, or Glu
60	65		Pro, Val, or Ala
63	68		Ala or Val
65	70		Thr, Ala, or Glu
66	71		Gln, Lys, Arg, or Glu
67	72		Leu, Met, or Val
68	73		Asn, Ser, Asp, or Gly
69	74		Ala, Pro, or Ser
70	75		Ile, Thr, Val, or Leu
71	76		Ser, Ala, or Pro
72	77		Val, Leu, Met, or Ile
74	79		Tyr or Phe
75	80		Phe, Tyr, Leu, or His
76	81		Asp, Asn, or Leu
77	82		Asp, Glu, Asn, Arg, or Ser
78	83		Ser, Gln, Asn, Tyr, or Asp
79	84		Ser, Asn, Asp, Glu, or Lys
80	85		Asn, Thr, or Lys
82	87		Ile, Val, or Asn
84	89		Lys or Arg
85	90		Lys, Asn, Gln, His, Arg, or Val
86	91		Tyr, Glu, or His
87	92		Arg, Gln, Glu, or Pro
88	93		Asn, Glu, Trp, or Asp
90	95		Val, Thr, Ala, or Ile
92	97		Arg, Lys, Val, Asp, Gln, or Glu
93	98		Ala, Gly, Glu, or Ser
95	100		Gly or Ala
97	102		His or Arg

FIG. 2B

AMINO ACID POSITION			
SEQ ID NO: 6	SEQ ID NO: 7	SEQ ID NO: 9	Xaa=
	2	2	Lys, Arg, Gln, Ser, His, Glu, Ala, or Cys
	3	3	Lys, Arg, Met, Thr, Leu, Tyr, or Ala
	4	4	His, Gln, Arg, Lys, Thr, Leu, Val, Pro, or Tyr
	5	5	Gln, Thr, His, Arg, Pro, Ser, Ala, Asn, Tyr, Lys, Asp, or Leu
1	6		Phe, Leu, or Glu
2	7		Tyr, Phe, His, Arg, Thr, Lys, Gln, Val, or Glu
3	8		Val, Ile, Leu, or Asp
4	9		Ser, Asp, Glu, Asn, or Phe
5	10		Phe or Glu
6	11		Arg, Gln, Lys, Ser, Glu, Ala, or Asn
7	12		Asp, Glu, Leu, Ala, or Gln
8	13		Leu, Val, Met, Ile, or Phe
9	14		Gly, His, or Lys
10	15		Trp or Met
11	16		Gln, Leu, His, Glu, Asn, Asp, Ser, or Gly
12	17		Asp, Asn, Ser, Lys, Arg, Glu, or His
13	18		Trp or Ser
14	19		Ile or Val
15	20		Ile or Val
16	21		Ala, Ser, Tyr, or Trp
18	23		Glu, Lys, Gln, Met, Pro, Leu, Arg, His, or Lys
19	24		Gly, Glu, Asp, Lys, Ser, Gln, Arg, or Phe
20	25		Tyr or Phe
21	26		Ala, Ser, Gly, Met, Gln, His, Glu, Asp, Leu, Asn, Lys, or Thr
22	27		Ala or Pro
23	28		Tyr, Phe, Asn, Ala, or Arg
24	29		Tyr, His, Glu, Phe, or Arg
26	31		Glu, Asp, Ala, Ser, Tyr, His, Lys, Arg, Gln, or Gly
28	33		Glu, Asp, Leu, Val, Lys, Gly, Thr, Ala, or Gln
30	35		Ala, Ser, Ile, Asn, Pro, Glu, Asp, Phe, Gln, or Leu
31	36		Phe, Tyr, Leu, Asn, Gly, or Arg
32	37		Pro, Ser, Ala, or Val
33	38		Leu, Met, Glu, Phe, or Val
34	39		Asn, Asp, Thr, Gly, Ala, Arg, Leu, or Pro
35	40		Ser, Ala, Glu, Asp, Thr, Leu, Lys, Gln, or His
36	41		Tyr, His, Cys, Ile, Arg, Asp, Asn, Lys, Ser, Glu, or Gly
37	42		Met, Leu, Phe, Val, Gly, or Tyr
38	43		Asn, Glu, Thr, Pro, Lys, His, Gly, Met, Val, or Arg
39	44		Ala, Ser, Gly, Pro, or Phe
40	45		Thr, Ser, Leu, Pro, His, or Met
41	46		Asn, Lys, Val, Thr, or Gln
42	47		His, Tyr, or Lys

FIG. 3A

AMINO ACID POSITION			
SEQ ID NO: 6	SEQ ID NO: 7	SEQ ID NO: 9	Xaa=
43	48		Ala, Thr, Leu, or Tyr
44	49		Ile, Thr, Val, Phe, Tyr, Met, or Pro
45	50		Val, Leu, Met, Ile, or His
46	51		Gln, Arg, or Thr
47	52		Thr, Ser, Ala, Asn, or His
48	53		Leu, Asn, or Ile
49	54		Val, Met, Leu, Pro, or Ile
50	55		His, Asn, Arg, Lys, Tyr, or Gln
51	56		Phe, Leu, Ser, Asn, Met, Ala, Arg, Glu, Gly, or Gln
52	57		Ile, Met, Leu, Val, Lys, Gln, Ala, or Tyr
53	58		Asn, Phe, Lys, Glu, Asp, Ala, Gln, Gly, Leu, or Val
54	59		Pro, Asn, Ser, Val, or Asp
55	60		Glu, Asp, Asn, Lys, Arg, Ser, Gly, Thr, Gln, Pro, or His
56	61		Thr, His, Tyr, Ala, Ile, Lys, Asp, Ser, Gly, or Arg
57	62		Val, Ile, Thr, Ala, Leu, or Ser
58	63		Pro, Gly, Ser, Asp, or Ala
59	64		Lys, Leu, Pro, Ala, Ser, Glu, Arg, or Gly
60	65		Pro, Ala, Val, Thr, or Ser
61	66		Cys, Val, or Ser
63	68		Ala, Val, or Thr
65	70		Thr, Ala, Glu, Val, Gly, Asp, or Tyr
66	71		Gln, Lys, Glu, Arg, or Val
67	72		Leu, Met, Thr, or Tyr
68	73		Asn, Ser, Gly, Thr, Asp, Glu, Lys, or Val
69	74		Ala, Pro, Gly, or Ser
70	75		Ile, Thr, Leu, or Val
71	76		Ser, Pro, Ala, Thr, Asn, or Gly
72	77		Val, Ile, Leu, or Met
74	79		Tyr, Phe, Arg, Thr, or Met
75	80		Phe, Tyr, His, Leu, Ile, Lys, Gln, or Val
76	81		Asp, Leu, Asn, or Glu
77	82		Asp, Ser, Arg, Asn, Glu, Ala, Lys, Gly, or Pro
78	83		Ser, Asn, Asp, Tyr, Ala, Gly, Gln, Met, Glu, or Lys
79	84		Ser, Asn, Glu, Asp, Val, Lys, Gly, Gln, or Arg
80	85		Asn, Lys, Thr, Pro, Val, Ile, Arg, Ser, or Gln
81	86		Val, Ile, Thr, or Ala
82	87		Ile, Asn, Val, Leu, Tyr, Asp, or Ala
83	88		Leu, Tyr, Lys, or Ile
84	89		Lys, Arg, Asn, Tyr, Phe, Thr, Glu, or Gly
85	90		Lys, Arg, His, Gln, Asn, Glu, or Val
86	91		Tyr, His, Glu, or Ile
87	92		Arg, Glu, Gln, Pro, or Lys
88	93		Asn, Asp, Ala, Glu, Gly, or Lys

FIG. 3B

AMINO ACID POSITION			--
SEQ ID NO: 6	SEQ ID NO: 7	SEQ ID NO: 9	Xaa=
89	91		Met or Ala
90	95		Val, Ile, Ala, Thr, Ser, or Lys
91	96		Val or Ala
92	97		Arg, Lys, Gln, Asp, Glu, Val, Ala, Ser, or Thr
93	98		Ala, Ser, Glu, Gly, Arg, or Thr
95	100		Gly, Ala, or Thr
97	102		His, Arg, Gly, Leu, or Ser

FIG. 3C

AMINO ACID POSITION	
SEQ ID NO: 3	Xaa=
2	Lys or Arg
3	Lys or Arg
11	Arg or Gln
16	Gln or Leu
19	Ile or Val
23	Glu or Gln
26	Ala or Ser
35	Ala or Ser
39	Asn or Asp
41	Tyr or Cys
50	Val or Leu
52	Ser or Thr
56	Phe or Leu
57	Ile or Met
58	Asn or Lys
60	Glu, Asp. or Asn
61	Thr, Ala, or Val
65	Pro or Ala
71	Gln or Lys
73	Asn or Ser
75	Ile or Thr
80	Phe or Tyr
82	Asp or Ser
84	Ser or Asn
89	Lys or Arg
91	Tyr or His
97	Arg or Lys

FIG. 4

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 27/00, C07K 14/51		A3	(11) International Publication Number: WO 98/51354 (43) International Publication Date: 19 November 1998 (19.11.98)
(21) International Application Number: PCT/US98/09951 (22) International Filing Date: 15 May 1998 (15.05.98) (30) Priority Data: 60/046,589 15 May 1997 (15.05.97) US 09/039,107 14 March 1998 (14.03.98) US (71) Applicant: CREATIVE BIOMOLECULES, INC. [US/US]; 45 South Street, Hopkinton, MA 01748 (US). (72) Inventors: RUEGER, David, C.; 81 Pine Hill Road, Southborough, MA 01772 (US). TUCKER, Marjorie, M.; 132 Robert Road, Holliston, MA 01746 (US). (74) Agent: MEYERS, Thomas, C.; Testa, Hurwitz & Thibault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 11 March 1999 (11.03.99)	
(54) Title: COMPOSITIONS FOR MORPHOGEN-INDUCED OSTEOGENESIS			
(57) Abstract Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/09951

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61L27/00 C07K14/51

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 11148 A (ANDREASSEN TROELS TORP ;JOERGENSEN JOERGEN PETER HOLMB (DK); BAK B) 8 August 1991 see claims ---	1,2,5-21
X	WO 93 25246 A (STRYKER CORP) 23 December 1993 see claims ---	1,2,5-21
X	EP 0 361 896 A (COLLAGEN CORP) 4 April 1990 see claims; examples ---	1,2,7,8
X	EP 0 616 814 A (SQUIBB BRISTOL MYERS CO) 28 September 1994 see claims ---	1,2,7,8
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 1999

Date of mailing of the international search report

22/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

Int'l. Application No

PCT/US 98/09951

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 00049 A (XOMA CORP) 7 January 1993 see claims ---	1,2,7,8
X	WO 96 40297 A (STRYKER CORP) 19 December 1996 see claims; examples ---	1,2
X	WO 95 33502 A (CREATIVE BIOMOLECULES INC) 14 December 1995 see claims ---	1,2
A	WO 94 10203 A (CREATIVE BIOMOLECULES INC) 11 May 1994 see claims ---	1,2
A	EP 0 309 241 A (COLLAGEN CORP) 29 March 1989 ---	
A	WO 95 27518 A (PLASMA BIOTAL LTD ;UNIV ABERDEEN (GB); MURALI SRIMATHI RAJAGOPALAN) 19 October 1995 -----	

INTERNATIONAL SEARCH REPORT

...ernational application No.

PCT/US 98/ 09951

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-35
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-35 (are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. J. Application No

PCT/US 98/09951

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9111148 A	08-08-1991	AU 7237491 A	21-08-1991
		AU 7318691 A	21-08-1991
		AU 7324391 A	21-08-1991
		WO 9111195 A	08-08-1991
		WO 9111196 A	08-08-1991
		PT 96652 A	29-01-1993
		PT 96653 A	26-02-1993
WO 9325246 A	23-12-1993	US 5344654 A	06-09-1994
		AU 668411 B	02-05-1996
		AU 4599793 A	04-01-1994
		CA 2138270 A	23-12-1993
		EP 0646022 A	05-04-1995
		JP 7504680 T	25-05-1995
EP 0361896 A	04-04-1990	US 5108436 A	28-04-1992
		AU 628083 B	10-09-1992
		AU 4233889 A	05-04-1990
		CA 1335958 A	20-06-1995
		JP 2218372 A	31-08-1990
		JP 2746290 B	06-05-1998
		JP 8332217 A	17-12-1992
		US 5258029 A	02-11-1993
		US 5207710 A	04-05-1993
EP 0616814 A	28-09-1994	AU 5905694 A	29-09-1994
		CA 2119090 A	27-09-1994
		FI 941396 A	27-09-1994
		JP 7002691 A	06-01-1995
		NO 940913 A	27-09-1994
WO 9300049 A	07-01-1993	US 5284756 A	08-02-1994
		AU 654316 B	03-11-1994
		AU 9162391 A	25-01-1993
		CA 2093790 A	21-12-1992
		EP 0546125 A	16-06-1993
		JP 7505039 T	08-06-1995
		US 5411941 A	02-05-1995
		US 5508263 A	16-04-1996
WO 9640297 A	19-12-1996	US 5674292 A	07-10-1997
		AU 6333596 A	30-12-1996
		CA 2223049 A	19-12-1996
		EP 0837701 A	29-04-1998
WO 9533502 A	14-12-1995	AU 2691995 A	04-01-1996
		CA 2191584 A	14-12-1995
		EP 0762903 A	19-03-1997
		JP 10504202 T	28-04-1998
WO 9410203 A	11-05-1994	AT 165213 T	15-05-1998
		AT 162078 T	15-01-1998
		AU 678380 B	29-05-1997
		AU 4795193 A	03-03-1994
		AU 4797193 A	03-03-1994
		AU 4995593 A	03-03-1994
		AU 5129293 A	12-04-1994
		AU 5129393 A	12-04-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/09951

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9410203 A		AU 5162393 A	12-04-1994
		AU 5290893 A	12-04-1994
		AU 681362 B	28-08-1997
		AU 5590094 A	24-05-1994
		CA 2141554 A	17-02-1994
		CA 2141555 A	17-02-1994
		CA 2141556 A	17-02-1994
		CA 2144513 A	31-03-1994
		CA 2147598 A	11-05-1994
		DE 69316379 D	19-02-1998
		DE 69316379 T	30-07-1998
		DE 69318166 D	28-05-1998
		DE 69318166 T	08-10-1998
		EP 0652953 A	17-05-1995
		EP 0653942 A	24-05-1995
		EP 0661933 A	12-07-1995
		EP 0665739 A	09-08-1995
		EP 0661987 A	12-07-1995
		EP 0680334 A	08-11-1995
		EP 0672064 A	20-09-1995
		ES 2118253 T	16-09-1998
		ES 2114073 T	16-05-1998
		GR 3026602 T	31-07-1998
		JP 7509611 T	26-10-1995
		JP 7509720 T	26-10-1995
		JP 7509721 T	26-10-1995
		JP 8501779 T	27-02-1996
		JP 8501558 T	20-02-1996
		JP 8501315 T	13-02-1996
		JP 8503198 T	09-04-1996
		WO 9403600 A	17-02-1994
		WO 9403075 A	17-02-1994
		WO 9403200 A	17-02-1994
		WO 9406447 A	31-03-1994
		WO 9406399 A	31-03-1994
		WO 9406449 A	31-03-1994
		WO 9406420 A	31-03-1994
		US 5834179 A	10-11-1998
		US 5652337 A	29-07-1997
		US 5652118 A	29-07-1997
EP 0309241 A	29-03-1989	US 4888366 A	19-12-1989
		AU 2275188 A	06-04-1989
		CA 1335177 A	11-04-1995
		DE 3886493 D	03-02-1994
		DE 3886493 T	14-04-1994
		ES 2060656 T	01-12-1994
		JP 1158964 A	22-06-1989
WO 9527518 A	19-10-1995	AU 2218395 A	30-10-1995
		DE 19581923 T	12-02-1998
		GB 2301531 A,B	11-12-1996
		US 5824087 A	20-10-1998
		ZA 9502880 A	21-12-1995